^
    Back
    Association details:
    Biomarker:BRAF wild-type
    Cancer:Rectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Rectal cancer: Systemic therapy for advanced or metastatic disease...FOLFOX + Cetuximab (KRAS/NRAS/BRAF WT only)...FOLFIRI + cetuximab (KRAS/NRAS/BRAF WT only)...FOLFIRINOX or mFOLFIRINOX + cetuximab...Irinotecan + cetuximab (KRAS/NRAS/BRAF WT only)
    Secondary therapy:
    FOLFIRINOX; FOLFIRI; irinotecan; FOLFOX
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy

    Excerpt:
    ...An ARMS-PCR proven KRAS, NRAS, PI3KCA and BRAF wild type; 3....
    Trial ID:
    NCT04923620